Skip to main content
Fig. 1 | Cardiovascular Diabetology

Fig. 1

From: The residual cardiorenal risk in type 2 diabetes

Fig. 1

Overview of the residual risk (red) and removed risk (green) of MACE (major adverse cardiovascular events), kidney outcome (in general a composite of sustained decline in the eGRF of at least 50%, end-stage kidney disease, and death from renal cause) and hospitalization from heart failure in intensive glucose trials (IGT) and CVOT (cardiovascular outcome trials) with newer drugs (GLP-1RA glucagon-like peptide-1 receptor agonists, SGLT-2i sodium-glucose trasporter-2 inhibitors, DPP-4i dipeptidyl-peptidase-4 inhibitors) in type 2 diabetes

Back to article page